<DOC>
	<DOC>NCT01105429</DOC>
	<brief_summary>BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Males and females of childbearing potential (willing to use an acceptable method of contraception), or females of nonchildbearing potential (i.e., postmenopausal or surgically sterile) Diagnosis of type 2 diabetes treated with metformin monotherapy on a stable regimen for at least 2 months Body Mass Index (BMI) of 18 to 40 kg/m2 Fasting glucose in the range of 100250 mg/dL Hemoglobin A1c (HbA1c) in the range of 6.5% 9.5% Clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Any significant acute or chronic medical illness other than stable and well controlled hypertension, microalbuminuria, dyslipidemia, or depression Past history of diabetic ketoacidosis and/or Cpeptide &lt; 1.0 ng/mL, hyperosmolar nonketotic syndrome, lactic acidosis, or recurrent hypoglycemia Any major surgery within 4 weeks of study drug administration Any gastrointestinal surgery that could impact upon the absorption of study drug Smoking more than 10 cigarettes per day Recent drug or alcohol abuse Women who are pregnant or breastfeeding Positive urine screen for drugs of abuse Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV1, 2 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>